Currently Enrolling Studies
Chronic Low Back Pain - Flier
Moderate-to-Severe chronic low back pain(CLBP) requiring opioid analgesia for an extended period of time.
Type 2 Diabetes -
The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in hemoglobin
A1c (HbA1c) from baseline after 24 weeks of exposure to Study Medication in type 2 diabetic subjects at
high risk of cardiovascular adverse events.
Chronic Low Back Pain -
The primary objective of the study is to evaluate the efficacy of Study Medication compared to placebo in reducing low back pain (LBP), as measured by the change from baseline at week 16 in the average daily LBP intensity (LBPI) numerical rating scale (NRS) score.
Osteoarthritis of the Hip or Knee -
This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group, Phase 3 study of the efficacy and safety of Study Medication for 16 weeks compared to placebo in subjects with osteoarthritis of the knee or hip.
Osteoarthritis of the Knee -
The study is a multi-center, multinational, randomized, double-blind, placebo-controlled, parallel-group
phase III clinical trial in subjects with OA of the knee. Subjects with diagnosed OA in at least one knee will be
randomized to treatment with either Study Medication or placebo.
This is a randomized, double-blind, double-dummy, placebo- and active controlled, multi-center
study of Study Medication in subjects with pain associated with fibromyalgia.
We are the sole owners of the information collected on this site. We only have access to/collect information that you voluntarily give us via email or other direct contact from you. We will not sell or rent this information to anyone.
We will use your information to respond to you, regarding the reason you contacted us. We will not share your information with any third party outside of our organization, other than as necessary to fulfill your request.